The new oral drug has been developed by a pharmaceutical company and its phase I of trial was earlier conducted in the USA. A similar study on phase II was also in progress at Kala-azar Medical Research Centre (KAMRC), Muzaffarpur, by a team led by Prof Shyam Sundar
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment